Dave Mullarkey joined Omniome in 2017 as the President, CEO, and Board Member of Omniome. His experience spans commercialization, business development, clinical research, and general management with a specific focus on developing and executing growth strategies for private life-sciences companies, building high-performing teams, and driving significant value creation within small, private start-ups and large, publicly traded companies.
Prior to joining Omniome, Dave was President and Chief Operating Officer of Ariosa Diagnostics, which was acquired by Roche where he then served as Lifecycle Leader, Site Head and member of Roche Sequencing Solutions Leadership Team. Prior to Ariosa and until 2013, Dave was Sr. Vice President and General Manager of Valeant Dermatology and led the largest and fastest growing business unit at Valeant Pharmaceuticals. Dave joined Valeant via acquisition of private, venture-backed company Dow Pharmaceutical Sciences. Earlier in his career, he had multiple leadership roles with Eli Lilly, Johnson & Johnson, Coopers and Lybrand Consulting, and SCIREX.
Dave received his BS in Applied Economics and Management at the Charles H. Dyson School of Management at Cornell University, and an MBA from the Kellogg Graduate School of Management at Northwestern University.